Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2012

Open Access 01-12-2012 | Original Article

Chromogranin A Cell Density as a Diagnostic Marker for Lymphocytic Colitis

Authors: Magdy El-Salhy, Doris Gundersen, Jan G. Hatlebakk, Trygve Hausken

Published in: Digestive Diseases and Sciences | Issue 12/2012

Login to get access

Abstract

Background

Lymphocytic colitis (LC) can be mistakenly diagnosed as irritable bowel syndrome (IBS). In a previous study on IBS, some patients showed extremely high colonic chromogranin A cell density. Further examination of these patients showed that they suffered from LC.

Aims

To investigate whether chromogranin A cell density is increased in LC patients and to examine the possibility of using this increase as a marker for the diagnosis of LC.

Methods

Fifty-seven patients diagnosed with LC and 54 controls were included in the study. Biopsies from the right and left colon were obtained from both patients and controls, which were immunostained using the Avidin–biotin-complex method for chromogranin A, and cell density was quantified.

Results

In both the right and left colon of patients with LC, the density of chromogranin A was significantly higher than in controls. This increase in chromogranin A cells occurs whether the number of these cells is expressed as number/mm2 epithelium or as number/field. Chromogranin A cell density for the right and left colon expressed as number of cells/mm2 epithelium or as cell number/field showed a high sensitivity and specificity as a diagnostic marker for LC.

Conclusions

Chromogranin A is a common marker for endocrine cells, and the present finding suggests that colonic hormones are involved in the pathophysiology of LC. The chromogranin cell density seems to be a good diagnostic marker with high sensitivity and specificity in both the right and left colon, thus sigmoidoscopy can be used in the diagnosis of LC using with this marker.
Literature
1.
go back to reference Liszka L, Woszczyk D, Pajak J. Histopathological diagnosis of microscopic colitis. J Gastroenterol Hepatol. 2006;21:792–797.PubMedCrossRef Liszka L, Woszczyk D, Pajak J. Histopathological diagnosis of microscopic colitis. J Gastroenterol Hepatol. 2006;21:792–797.PubMedCrossRef
2.
go back to reference Fernandez-Banares F, Salas A, Forne M, et al. Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am J Gastroenterol. 1999;94:418–423.PubMed Fernandez-Banares F, Salas A, Forne M, et al. Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am J Gastroenterol. 1999;94:418–423.PubMed
3.
go back to reference Chande N, MacDonald JK, McDonald JW. Interventions for treating microscopic colitis: a Cochrane inflammatory bowel disease and functional bowel disorders review group systematic review of randomized trials. Am J Gastroenterol. 2009;104:235–241.PubMedCrossRef Chande N, MacDonald JK, McDonald JW. Interventions for treating microscopic colitis: a Cochrane inflammatory bowel disease and functional bowel disorders review group systematic review of randomized trials. Am J Gastroenterol. 2009;104:235–241.PubMedCrossRef
6.
go back to reference Yen EF, Pardi DS. Review article: microscopic colitis-lymphocytic, collagenous and mast cell colitis. Allment Pharmacol Ther. 2011;34:21–32.CrossRef Yen EF, Pardi DS. Review article: microscopic colitis-lymphocytic, collagenous and mast cell colitis. Allment Pharmacol Ther. 2011;34:21–32.CrossRef
7.
go back to reference Agnarsdottir M, Gunnlaugsson O, Orvar KB, et al. Collagenous and lymphocytic colitis in Iceland. Dig Dis Sci. 2002;47:1122–1128.PubMedCrossRef Agnarsdottir M, Gunnlaugsson O, Orvar KB, et al. Collagenous and lymphocytic colitis in Iceland. Dig Dis Sci. 2002;47:1122–1128.PubMedCrossRef
8.
go back to reference Fernandez-Banares F, Forne M, Esteve M, et al. Collagenous colitis and lymphocytic colitis in Terrassa, Spain: an epidemilogical Study 1993–1996. Gastroenterology. 1997;122:A15. Fernandez-Banares F, Forne M, Esteve M, et al. Collagenous colitis and lymphocytic colitis in Terrassa, Spain: an epidemilogical Study 1993–1996. Gastroenterology. 1997;122:A15.
9.
go back to reference Olesen M, Eriksson S, Bohr J, et al. Microscopic colitis: a common diarrheal disease. An epidemiological study in Örebro, Sweden, 1993–1998. Gut. 1995;37:394–397. Olesen M, Eriksson S, Bohr J, et al. Microscopic colitis: a common diarrheal disease. An epidemiological study in Örebro, Sweden, 1993–1998. Gut. 1995;37:394–397.
10.
go back to reference El-Salhy M, Halwe J, Lomholt-Beck B, Gundersen D. The prevalence of inflammatory bowel diseases and microscopic colitis and colorectal cancer in patients with irritable bowel syndrome. Gastroenterol Insights. 2011;3:7–10. doi:10.4081/gi.2011.e3.CrossRef El-Salhy M, Halwe J, Lomholt-Beck B, Gundersen D. The prevalence of inflammatory bowel diseases and microscopic colitis and colorectal cancer in patients with irritable bowel syndrome. Gastroenterol Insights. 2011;3:7–10. doi:10.​4081/​gi.​2011.​e3.CrossRef
11.
go back to reference El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Irritable bowel syndrome. New York: Nova Science Publisher; 2012. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Irritable bowel syndrome. New York: Nova Science Publisher; 2012.
12.
go back to reference El-Salhy M, Lomholt-Beck B, Hausken T. Chromogranin as a tool in the diagnosis of irritable bowel syndrome. Scan J Gastroenterol. 2010;45:1435–1439.CrossRef El-Salhy M, Lomholt-Beck B, Hausken T. Chromogranin as a tool in the diagnosis of irritable bowel syndrome. Scan J Gastroenterol. 2010;45:1435–1439.CrossRef
13.
go back to reference El-Salhy M, Lomholt-Beck B, Gundersen D. High chromgranin A cell density in the colon of patients with lymphocytic colitis. Mol Med Rep. 2011;4:603–605. El-Salhy M, Lomholt-Beck B, Gundersen D. High chromgranin A cell density in the colon of patients with lymphocytic colitis. Mol Med Rep. 2011;4:603–605.
14.
go back to reference Goya PK. Hirano I mechanisms of disease: the enteric nervous system. N Engl J Med. 1996;334:1106–1615.CrossRef Goya PK. Hirano I mechanisms of disease: the enteric nervous system. N Engl J Med. 1996;334:1106–1615.CrossRef
15.
go back to reference McConalouge K, Furness JB. Gastrointestinal neurotransmitters. Baillieres Clin Endocrinol Metab. 1994;8:51–76.CrossRef McConalouge K, Furness JB. Gastrointestinal neurotransmitters. Baillieres Clin Endocrinol Metab. 1994;8:51–76.CrossRef
16.
17.
go back to reference El-Salhy M. Gut neuroendocrine system in diabetes gastroenteropathy: possible role in pathophysiology and clinical implications. In: Ashley M, ed. Focus on Diabetes Research. New York: Nova Science Publisher; 2006:79–102. El-Salhy M. Gut neuroendocrine system in diabetes gastroenteropathy: possible role in pathophysiology and clinical implications. In: Ashley M, ed. Focus on Diabetes Research. New York: Nova Science Publisher; 2006:79–102.
18.
go back to reference Taupenot L, Harper KL, O’Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134–1149.PubMedCrossRef Taupenot L, Harper KL, O’Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134–1149.PubMedCrossRef
19.
go back to reference Wicdenmann B, Huttner WB. Synaptophysin and chromogranin/secretogranins-widespread constituents of distinct types of neuroendocrine vesicales and new tools in tumor diagnosis. Virchows Arch B Cell Pathol. 1989;58:95–121.CrossRef Wicdenmann B, Huttner WB. Synaptophysin and chromogranin/secretogranins-widespread constituents of distinct types of neuroendocrine vesicales and new tools in tumor diagnosis. Virchows Arch B Cell Pathol. 1989;58:95–121.CrossRef
20.
go back to reference Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev. 1991;12:181–188.PubMedCrossRef Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev. 1991;12:181–188.PubMedCrossRef
21.
go back to reference El-Salhy M, Sandsrøm E, Nästrøm E, et al. Application of computer image analysis in endocrine cell quantification. Histochemical J. 1997;29:249–256.CrossRef El-Salhy M, Sandsrøm E, Nästrøm E, et al. Application of computer image analysis in endocrine cell quantification. Histochemical J. 1997;29:249–256.CrossRef
22.
go back to reference Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol. 2010;161:19–27.PubMed Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol. 2010;161:19–27.PubMed
23.
go back to reference Zhang D, Shooshtarizadeh P, Laventie BJ, et al. Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2. PLoS ONE. 2009;4:e4501.PubMedCrossRef Zhang D, Shooshtarizadeh P, Laventie BJ, et al. Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2. PLoS ONE. 2009;4:e4501.PubMedCrossRef
24.
go back to reference Egger M, Beer AG, Theurl L, et al. Monocyte migration: a novel effect and signaling pathway of catestatin. Eur J Pharmacol. 2008;598:104–111.PubMedCrossRef Egger M, Beer AG, Theurl L, et al. Monocyte migration: a novel effect and signaling pathway of catestatin. Eur J Pharmacol. 2008;598:104–111.PubMedCrossRef
25.
go back to reference Feistritzer C, Mosheimer BA, Colleselli D, Wiedermann CI, Kahler CM. Effects of the neuropeptide secretoneurin on natural kill cell migration and cytokine release. Regul Pept. 2005;126:195–201.PubMedCrossRef Feistritzer C, Mosheimer BA, Colleselli D, Wiedermann CI, Kahler CM. Effects of the neuropeptide secretoneurin on natural kill cell migration and cytokine release. Regul Pept. 2005;126:195–201.PubMedCrossRef
26.
go back to reference Ferrero E, Magni E, Curnis F, Villa A, Ferrro ME, Corti A. Regulation of endothelial cells barrier function by chromogranin A. Ann NY Acad Sci. 2002;971:355–358.PubMedCrossRef Ferrero E, Magni E, Curnis F, Villa A, Ferrro ME, Corti A. Regulation of endothelial cells barrier function by chromogranin A. Ann NY Acad Sci. 2002;971:355–358.PubMedCrossRef
27.
go back to reference El-Salhy M, Danielsson Å, Stenling R, Grimelius L. Colonic endocrine cells in inflammatory bowel disease. J Int Med. 1997;242:413–419.CrossRef El-Salhy M, Danielsson Å, Stenling R, Grimelius L. Colonic endocrine cells in inflammatory bowel disease. J Int Med. 1997;242:413–419.CrossRef
28.
go back to reference Sciola V, Maaironi S, Conte D, et al. Plasmachromogranin A in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:867–871.PubMedCrossRef Sciola V, Maaironi S, Conte D, et al. Plasmachromogranin A in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:867–871.PubMedCrossRef
29.
go back to reference Sidhu R, Drew K, Lobo AJ. Elevated serum chromogranin A in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): A shared model for pathogenesis? Inflamm Bowel Dis. 2010;16:361.PubMed Sidhu R, Drew K, Lobo AJ. Elevated serum chromogranin A in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): A shared model for pathogenesis? Inflamm Bowel Dis. 2010;16:361.PubMed
30.
Metadata
Title
Chromogranin A Cell Density as a Diagnostic Marker for Lymphocytic Colitis
Authors
Magdy El-Salhy
Doris Gundersen
Jan G. Hatlebakk
Trygve Hausken
Publication date
01-12-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2249-6

Other articles of this Issue 12/2012

Digestive Diseases and Sciences 12/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.